Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies
Status:
Recruiting
Trial end date:
2024-03-10
Target enrollment:
Participant gender:
Summary
This is a single-center, open-label, single-arm study to evaluate the primary safety and
efficacy of anti-CD19 chimeric antigen receptor(CAR)-modified NK cells(CAR-NK-CD19) in
patients with relapsed or refractory hematological malignancies.